| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Binding IC50: 0.3 nM (MCH1R) IC50: 1.5 nM (MCH1R)[1]
MCH (human, mouse, rat) TFA targets the melanin-concentrating hormone receptors, exhibiting binding IC50 values of 0.3 nM for MCH1R and 1.5 nM for MCH2R, with functional EC50 values of 3.9 nM and 88.7 nM for MCH1R and MCH2R, respectively. |
|---|---|
| ln Vitro |
The peptide shows potent agonist activity at MCH1R and MCH2R. It activates G protein-coupled receptor signaling pathways leading to intracellular calcium mobilization and inhibition of cAMP accumulation. CHO cells expressing MCH2R are highly sensitive to MCH activation.
|
| ln Vivo |
MCH (human, mouse, rat) TFA increases food intake when administered centrally in rodent models. In vivo studies demonstrate its orexigenic effects, with administration leading to enhanced feeding behavior and modulation of energy balance through hypothalamic pathways.
|
| Enzyme Assay |
Not available. Standard MCH receptor binding assays involve incubating radiolabeled MCH (e.g., 125I-MCH) with membrane preparations from cells expressing MCH1R or MCH2R (10-50 microg protein), using 1-10 nM labeled ligand with varying concentrations of unlabeled MCH (1 pM to 10 microM), incubating at room temperature for 60-120 minutes, then separating bound from free radioactivity by filtration.
|
| Cell Assay |
Not available. For functional assays, typical protocols involve loading MCH receptor-expressing CHO or HEK293 cells with calcium-sensitive dyes (e.g., Fluo-4 AM), washing with assay buffer, adding MCH at concentrations ranging from 0.1 nM to 10 microM, and measuring fluorescence increase using a plate reader or imaging system.
|
| Animal Protocol |
Not available. For in vivo studies, standard protocols involve intracerebroventricular (ICV) injection of MCH (1-10 ug) in rodents, followed by monitoring food intake at 1, 2, 4, and 24 hours post-injection. Body weight changes and locomotor activity may also be assessed over 1-7 days.
|
| ADME/Pharmacokinetics |
Not available. As a neuropeptide with TFA salt, pharmacokinetic properties are typical of peptide therapeutics: rapid degradation by proteases in circulation, limited blood-brain barrier penetration, and short half-life (minutes to hours) when administered peripherally.
|
| Toxicity/Toxicokinetics |
Not available. MCH is an endogenous neuropeptide with well-tolerated effects at physiological concentrations. Pharmacological doses administered ICV in rodents typically do not produce overt toxicity, though specific toxicological data for the TFA salt are not reported.
|
| References | |
| Additional Infomation |
MCH (human, mouse, rat) TFA is a research-grade peptide used to study MCH receptor biology, feeding behavior, energy metabolism, and neuroendocrine regulation. It has not been approved for clinical use or advanced to human trials. The TFA salt enhances solubility and stability for laboratory applications.
|
| Molecular Formula |
C107H161F3N30O28S4
|
|---|---|
| Molecular Weight |
2500.86
|
| Related CAS # |
MCH(human, mouse, rat);128315-56-0
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~39.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (1.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3999 mL | 1.9993 mL | 3.9986 mL | |
| 5 mM | 0.0800 mL | 0.3999 mL | 0.7997 mL | |
| 10 mM | 0.0400 mL | 0.1999 mL | 0.3999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
